Kodiak Sciences Inc. (FRA:K27)

Market Cap	1.99B +1,093.7%
Revenue (ttm)	n/a
Net Income	-185.24M
EPS	-3.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	65
Open	33.18
Previous Close	29.64
Day's Range	33.18 - 38.78
52-Week Range	1.72 - 38.78
Beta	n/a
RSI	78.58
Earnings Date	Mar 26, 2026

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 123
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: K27

Financial Performance

Financial numbers in USD